Immunoglobulin A nephropathy (IgAN) is the most common type of glomerulonephritis (GN), with a higher prevalence in Asia compared with the Western world.^1-3 The current mainstay of IgAN treatment is mainly optimized supportive care.¹ Despite the use of renin-angiotensin-aldosterone system (RAAS) inhibitors and immunosuppressants, many IgAN patients still progress to kidney failure.⁴ Recently, the DAPA-CKD trial has unprecedentedly demonstrated the renal-protective benefits of dapagliflozin among IgAN patients with or without type 2 diabetes (T2D), offering an effective alternative to IgAN patients for improved renal outcomes.⁴ In an interview with Omnihealth Practice, Dr. Chan, Ting-Pong Anthony adopted this novel option in his practice and shared a clinical case to demonstrate the benefits of dapagliflozin in a young patient whose IgAN was uncontrolled with conventional medications.